Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts-Reference-Cited by-同舟云学术

Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts

Published:2013-10-14 Issue:3 Volume:34 Page:367-378
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Thulin Petra¹,Nordahl Gunnar²,Gry Marcus²,Yimer Getnet³,Aklillu Eleni⁴,Makonnen Eyasu³,Aderaye Getachew⁵,Lindquist Lars⁶,Mattsson C. Mikael⁷,Ekblom Björn⁷,Antoine Daniel J.⁸,Park B. Kevin⁸,Linder Stig⁹,Harrill Alison H.¹⁰,Watkins Paul B.¹⁰,Glinghammar Björn¹¹,Schuppe-Koistinen Ina¹

Affiliation:

1. AstraZeneca R&D; Innovative Medicines Personalised Healthcare & Biomarkers; Science for Life Laboratory; Solna Sweden

2. Former AstraZeneca R&D; Global Safety Assessment; Molecular Toxicology; Södertälje Sweden

3. Department of Pharmacology; Faculty of Medicine; Addis Ababa University; Addis Ababa Ethiopia

4. Division of Clinical Pharmacology; Department of Laboratory Medicine; Karolinska Institutet; Karolinska University Hospital; Huddinge Sweden

5. Department of Internal Medicine; Faculty of Medicine; Addis Ababa University; Addis Ababa Ethiopia

6. Department of Medicine; Division of Infectious Diseases; Karolinska Institutet; Karolinska University Hospital; Huddinge Sweden

7. Åstrand Laboratory of Work Physiology; Swedish School of Sport and Health Sciences; Karolinska Institutet; Stockholm Sweden

8. MRC Centre for Drug Safety Science; Department of Molecular & Clinical Pharmacology; University of Liverpool; Liverpool UK

9. Department of Oncology-Pathology; Karolinska Institutet; Karolinska University Hospital; Solna Sweden

10. School of Pharmacy; University of North Carolina at Chapel Hill; Chapel Hill NC USA

11. AstraZeneca R&D; Drug Safety & Metabolism; Mölndal Sweden

Funder

European and Developing Countries Clinical Trial Partnership

Swedish Research Council

National Center for Advancing Translational Sciences

National Institutes of Health

Medical Research Council

Wellcome Trust Research Fellowship

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.12322/fullpdf

Reference52 articles.

1. FDA Guidance for industry: drug-induced liver injury: premarketing clinical evaluation 2009 http://www.fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdf

2. Review article: drug-induced liver injury in clinical practice;Bjornsson;Aliment Pharmacol Ther,2010

3. Transaminase activity in human blood;Karmen;J Clin Invest,1955

4. Concordance of the toxicity of pharmaceuticals in humans and in animals;Olson;Regul Toxicol Pharmacol,2000

5. Catalytic enzyme activity concentration in tissues of man, dog, rabbit, guinea pig, rat and mouse. Approach to a quantitative diagnostic enzymology, III. Communication;Lindena;J Clin Chem Clin Biochem,1986

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A brief overview of drug-induced liver damage;The Egyptian Journal of Internal Medicine;2024-05-30

2. Cytokeratin-18 is a sensitive biomarker of alanine transaminase increase in a placebo-controlled, randomized, crossover trial of therapeutic paracetamol dosing (PATH-BP biomarker substudy);Toxicological Sciences;2024-03-23

3. Idiosyncratic Adverse Drug Reactions;Reference Module in Biomedical Sciences;2024

4. KRT17 serves as an oncogene biomarker of poor survival in patients with hepatocellular carcinoma;Biomedical Technology;2023-09

5. Potential of circulating receptor-interacting protein kinase 3 levels as a marker of acute liver injury;Scientific Reports;2023-08-28